2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministration
2008
Relationship between recovery of frontocortical 5HT2A receptor density and PI hydrolysis after chronic treatment
Schindler E, Aloyo V, Harvey J. Relationship between recovery of frontocortical 5HT2A receptor density and PI hydrolysis after chronic treatment. The FASEB Journal 2008, 22: 621-621. DOI: 10.1096/fasebj.22.2_supplement.621.Peer-Reviewed Original ResearchReceptor densityPI hydrolysisControl levelsRecovery periodRecovery daysChronic drug administrationDOI treatmentSerotonin2A receptorsAgonist DOIChronic treatmentLast injectionDrug AdministrationPharmacologic manipulationPhosphatidylinositol hydrolysisTime pointsVivo studiesFurther studiesTissue slicesDaysReceptorsTreatmentPeriodLevelsMajor signaling systemsAdministration